Clip device accomplishes endovascular, non-surgical repair of faulty heart valve

March 09, 2004

March 9, 2004--A tiny metallic clip that can be delivered and attached to the heart's mitral valve with a catheter may eliminate the need for open-heart surgery in some patients who suffer from significant mitral regurgitation (MR). A debilitating condition, MR occurs when the valve, which allows blood to move through the heart, fails to close properly.

Early experience with the clip, which is being evaluated under an FDA approved Investigational Device Exemption, has been encouraging, says Principal Investigator Ted Feldman, MD, Director of the Cardiac Catheterization Lab at Evanston Hospital, flagship of the Evanston Northwestern Healthcare system. Evalve, Inc. (Redwood City, CA) developed and manufactures the system.

Dr. Feldman will present results of the Phase I trial at 9 a.m. CST Tuesday, March 9, at the American College of Cardiology Conference, Morial Convention Center, Hall A, New Orleans. The presentation, part of the Late-Breaking Clinical Trials II group, is titled Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique: Phase I US Trial Results.

To date, a total of 10 percutaneous mitral valve repairs using this device have been performed nationwide. Dr. Feldman performed the first U.S. procedure in Evanston Hospital's Cardiac Catheterization Laboratory. Other U.S. investigators participating in the trial are: Howard Herrmann, MD, University of Pennsylvania; Peter Block, MD, Emory University Hospital, Atlanta; Pat Whitlow, MD, Cleveland Clinic Foundation; William Gray, MD; Swedish Medical Center, Seattle; Kenneth Kent, MD, Washington Hospital Center, Washington, DC; and Hal Wasserman, MD, Columbia University Medical Center, New York.

"Collectively, we have used the clip in 10 patients without complications during the procedure. Prior to the catheter procedure all 10 patients had MR serious enough to require surgery. The majority of the patients treated with the device had their MR significantly reduced so as to no longer need surgery. The patients who did not receive optimal MR control with the clip were able to have routine, successful mitral valve surgery as previously indicated," explains Dr. Feldman.

In chronic MR, blood leaks backward with each heartbeat, requiring the heart to work harder. It's a progressive disorder that affects approximately 4 million people in the United States. Approximately 250,000 patients develop significant mitral regurgitation annually in the US.

Patients with significant mitral regurgitation eventually become so weakened by the condition that they require open-heart surgery with cardiopulmonary bypass. Approximately 50,000 people a year have open, arrested-heart mitral valve surgery.

To be eligible for the investigational procedure, candidates must have moderate to severe or severe mitral regurgitation and be experiencing symptoms (fatigue, chest pain, shortness of breath); or, lacking these symptoms, they must have a weakened left ventricle (heart muscle).

Performed in a cardiac catheterization laboratory, the initial procedures have taken 2-4 hours. Under general anesthesia, a catheter (a thin, flexible plastic tube) introduced through the skin in the thigh area, is guided from the femoral vein to the affected area of the heart. The clip is precisely steered into place and attached to the mitral valve, helping it to close properly. Once the clip is securely attached, the catheter is removed. The procedure is performed using echocardiography and fluoroscopy. The hospital stay has been one to two nights and patients generally returned to normal activity within one week. As experience with the procedure grows, Dr. Feldman expects that it will require less time and may utilize local anesthesia. In follow-up visits with patients who received the clip, Dr. Feldman has observed the device working according to design. "When I saw our second patient for follow-up, he had no heart murmur at all!" Dr. Feldman says.

"This new clip is one of the interventional cardiology devices in the pipeline that will change the face of cardiology in the coming years," says Dr. Feldman. "We are beginning to see an array of devices that are intended to repair or replace malfunctioning structures of the heart without surgical intervention. Recovery times will be reduced from weeks to just days," he adds.
Evanston Northwestern Healthcare ( is comprised of Evanston Hospital, Glenbrook Hospital, Highland Park Hospital, ENH Medical Group, ENH Foundation, ENH Home Services and ENH Research Institute. Nationally recognized, the healthcare organization has been ranked by Solucient among the TOP 15 Major Teaching Hospitals and Top 100 Hospitals nationally for eight consecutive years. SMG Marketing ranked it fifth among the nation's Top 100 Integrated Delivery Systems. The organization provides care across a comprehensive range of services: physician offices, hospitals, home care and hospice. Through its affiliation with Feinberg School of Medicine, Northwestern University, Evanston Northwestern Healthcare supports extensive medical education and research programs.

Session 409-7, 9 AM Tuesday, March 9, Hall A,
Ernest N. Morial Convention Center, New Orleans

10:30-11:30 a.m. Tuesday, 3/9, Room 242, Morial Convention Ctr.

Evanston Northwestern Healthcare

Related Chest Pain Articles from Brightsurf:

New approach helps EMTs better assess chest pain en route to hospital
A study conducted at Wake Forest Baptist Health shows that on-scene use of a new protocol and advanced diagnostic equipment can help paramedics better identify patients at high risk for adverse cardiac events.

Brain activity during psychological stress may predict chest pain in people with heart disease
The brain's reaction to stress could be an important indicator of angina (chest pain) among people with known heart disease.

Chest pain, stress tests warrant attention even if arteries are clear
Patients who experience chest pain and have abnormal results on a cardiac stress test but who do not have blocked arteries often experience changes in their symptoms and stress test results over time, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Women carry heavier burden of chest pain, but less artery narrowing
Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) have significantly more chest pain caused by plaque build-up, yet less extensive disease as compared with men, according to new research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

More isn't better when it comes to evaluating chest pain
New and more effective tests are needed to help predict heart attacks and other major cardiac events in patients with chest pain, the second most common reason for emergency department visits in the US.

Artificial intelligence could prevent unneeded tests in patients with stable chest pain
Artificial intelligence (AI) could prevent unnecessary diagnostic tests in patients with stable chest pain, according to research presented today at ICNC 2019.

Kaiser Permanente improves emergency care for patients with chest pain
Emergency physicians at Kaiser Permanente hospitals in Southern California reduced hospital admissions and cardiac stress testing by using new criteria to assess the level of risk patients with chest pain have for subsequent cardiac events.

Treatment for underdiagnosed cause of debilitating chest pain
Researchers find an effective way to treat an underdiagnosed condition that can cause heart attack and heart-attack-like symptoms.

Diagnostic protocol effective in identifying ED patients with acute chest pain
A relatively new accelerated diagnostic protocol is effective in identifying emergency department patients with acute chest pain who can be safely sent home without being hospitalized or undergoing comprehensive cardiac testing, according to researchers at Wake Forest Baptist Medical Center.

Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death
A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine (used to treat chest pain; brand name Ranexa®) was safe but didn't decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population.

Read More: Chest Pain News and Chest Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to